C4 Therapeutics (CCCC) Earnings Analysis

C4 Therapeutics (CCCC) next reports earnings on 2026-08-06, consensus EPS -0.23 USD. Last quarter (2026-02-26) it beat with EPS -0.18 USD vs -0.31 USD est (+41.9%). It has beaten estimates in 4/6 recent quarters (67%). Trailing P/E -3.14.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does CCCC next report earnings?

Next earnings date2026-08-06
Consensus EPS estimate-0.23 USD
Revenue estimate0.01B

CCCC earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-02-26-0.18 USD-0.31 USD+41.9%Beat
2025-11-06-0.44 USD-0.40571 USD-8.5%Miss
2025-08-07-0.37 USD-0.38 USD+2.6%Beat
2025-02-27-0.49 USD-0.45 USD-8.9%Miss
2024-10-31-0.35 USD-0.4 USD+12.5%Beat
2024-08-01-0.26 USD-0.37 USD+29.7%Beat

Beat rate: 4/6 (67%) over reported quarters with consensus data.

CCCC valuation and analyst view

Trailing P/E-3.14
Trailing EPS-0.82333 USD
Price / book2.01
Dividend yield0.00%
Market cap0.31B
Analyst consensusBuy (10 buy / 3 hold / 1 sell)
Avg price target7.67 USD

Related research pages

Frequently asked questions

When is C4 Therapeutics (CCCC)'s next earnings date?

C4 Therapeutics is next scheduled to report on 2026-08-06, with a consensus EPS estimate of -0.23 USD and revenue estimate of 0.01B.

Did CCCC beat earnings last quarter?

In its 2026-02-26 report, CCCC posted EPS of -0.18 USD versus a -0.31 USD estimate — a beat of 41.9%.

What is CCCC's earnings track record?

Over the last 6 reported quarters with consensus data, CCCC beat estimates 4 times (67%).

What is CCCC's current P/E ratio and EPS?

CCCC trades at a trailing P/E of -3.14 on trailing EPS of -0.8233302905570438 USD.

What do analysts rate CCCC?

Analyst consensus is "Buy" across 14 ratings (0 strong buy, 10 buy, 3 hold, 1 sell, 0 strong sell). Average 12-month price target: 7.67 USD.